Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00041769 · ClinicalTrials.gov registry record · Phase 3
Using Drug Levels in the Blood to Guide Therapy in HIV Infected Patients Taking a Protease Inhibitor
A Phase 3 study of HIV Infections, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 3
- Development phase
- 360
- Enrollment target
- 20
- Study locations
NCT00041769: Completed Phase 3 study of HIV Infections, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
NCT00041769 is a Phase 3 study of HIV Infections that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 360 participants, below the 445-participant average among 542 other HIV Infections trials with a reported enrollment target (19% lower). The trial reports 20 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00041769, a Phase 3 study of HIV Infections, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 360 participants
- Enrollment target
- 20
- Study locations
Study Summary
Drug resistance testing can be used to see which anti-HIV drugs are likely to suppress the growth of HIV and to select an anti-HIV regimen for HIV infected patients who have failed previous drug regimens. Therapeutic drug monitoring (TDM) is a process that involves measuring blood levels of a drug and may further increase the benefits that resistance testing offers by optimizing protease inhibitor (PI) drug concentrations. The purpose of this study is to determine whether changing the dose of PIs, as indicated by TDM, reduces the viral load in PI-experienced patients. Hypothesis: Treatment-naive study participants who undergo TDM and whose clinicians' interpret their TDM results and adjust their PI doses will have better virologic response rates and decreased toxicities (and thus better treatment outcomes) than participants who do not undergo TDM.
Conditions Studied
Interventions
- PROCEDURE Therapeutic Drug Monitoring (TDM)
Study Locations (20)
California
- Univ of Southern California - Los Angeles
- UCLA School of Medicine - Los Angeles
- Univ of California, San Diego Antiviral Research Center (AVRC) - San Diego
- Univ of California San Francisco - San Francisco
- San Mateo County AIDS Program - Stanford
- Santa Clara Valley Med Ctr - Stanford
- Willow Clinic - Stanford
Indiana
- Methodist Hosp of Indiana - Indianapolis
- Indiana Univ Hosp - Indianapolis
- Wishard Hosp - Indianapolis
Illinois
- Northwestern Univ - Chicago
- The CORE Ctr - Chicago
Maryland
- Univ of Maryland, Institute of Human Virology - Baltimore
- Johns Hopkins Univ - Baltimore
Massachusetts
- Harvard (Masschusetts General Hosp) - Boston
- Beth Israel Deaconess-West Campus - Boston
Alabama
- Univ of Alabama at Birmingham - Birmingham
Colorado
- Univ of Colorado Health Sciences Ctr - Denver
Florida
- Univ of Miami - Miami
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 360 participants |
| Start Date | 2002-06 |
| Est. Completion | 2007-08 |
| Phase | Phase 3 |
What the finished NCT00041769 record still lists
NCT00041769 is an interventional study that assigns participants to a tested intervention. The registered 360 participants enrollment target is mid-sized for trials with a published cap, below the 445-participant average among 542 other HIV Infections trials with a reported enrollment target (19% lower).
The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 1 intervention - of which Therapeutic Drug Monitoring (TDM) is the first listed.
NCT00041769 names 20 study sites across 9 states, led by California, Indiana, Illinois.
Frequently Asked Questions
What is clinical trial NCT00041769 about?
NCT00041769 is a clinical study titled "Using Drug Levels in the Blood to Guide Therapy in HIV Infected Patients Taking a Protease Inhibitor". Drug resistance testing can be used to see which anti-HIV drugs are likely to suppress the growth of HIV and to select an anti-HIV regimen for HIV infected patients who have failed previous drug regimens. Therapeutic drug monitoring (TDM) is a process that involves measuring blood levels of a drug a...
What is the current status of trial NCT00041769?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 360 participants. The study started on 2002-06. Estimated completion is 2007-08.
What conditions does trial NCT00041769 study?
This clinical trial studies the following conditions: HIV Infections.
What interventions are being tested in trial NCT00041769?
The interventions under investigation include: Therapeutic Drug Monitoring (TDM) (PROCEDURE).
Who is sponsoring clinical trial NCT00041769?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00041769 being conducted?
This trial has 20 study locations across Alabama, California, Colorado, Florida, Hawaii. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00041769's enrollment target sits among peer trials
360 94th of 542 higher than 446 of 542 other HIV Infections trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other HIV Infections trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1
RECRUITING · Phase 3
-
Testing a Real-time Electronic Antiretroviral Adherence Monitoring Intervention
RECRUITING · Phase 3
-
SmartSteps: A Context-Aware, PrEP Adherence Intervention for Individuals With Substance Use Disorder
RECRUITING · Phase 3
-
Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected Adults
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Evaluate Efficacy, Safety and Tolerability in Antiretroviral Therapy (ART)-Experienced Participants of at Least 50 Years of Age Living With Human Immunodeficiency Virus (HIV) With Virologic Suppression Who Switch to DTG/3TC FDC From BIC/FTC/TAF
ACTIVE NOT RECRUITING · Phase 3
-
The LATITUDE Study: Long-Acting Therapy to Improve Treatment SUccess in Daily LifE
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02747836 · 360 participants
Ultrasound Analysis of Human Carpal Tunnel System
- NCT04089046 · 360 participants · NA
Telemedicine Enhanced Asthma Management - Uniting Providers for Teens (TEAM-UP for Teens)
- NCT04130503 · 360 participants · NA
The Recovery in Stroke Using PAP Study
- NCT04160000 · 360 participants · Phase 4
Treatment Of Atrial Fibrillation In Preserved Cardiac Function Heart Failure
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia